Advertisement
The clinical trials are expected to enroll approximately 300 adults and200 children with dosing and follow-up occurring over a six month period. TheCompanies anticipate that it will take approximately nine to twelve months tocomplete the trial and receive regulatory approval.
Advertisement
Mr. Weidong Yin, Chairman, President and CEO, commented, "As a developerof world-class vaccines, our strategy has been to provide high qualityvaccines to people around the world. Sinovac is continuing to pursuestrategic distribution partnerships that enable us to enter attractive marketsoutside of China by leveraging our GMP-certified manufacturing capabilities,which are capable of providing low cost, highly scalable production. We lookforward to seeing the Ukrainian market contribute to our sales growth."
About Biolik
"Biolik" is well known in Ukraine and ex-USSR as the manufacturer of manyimmunobiological and medicinal products. Its products are delivered to allregions of Ukraine, Russia and countries of the Commonwealth of IndependentStates. Biolik constantly focuses on the modernization of manufacturing andimprovement of technological schemes. Industrial shops and sites that meetinternational standards are commissioned annually. Today, Biolik is the onlyenterprise in Ukraine that manufactures vaccines for prophylaxis ofdiphtheria, tetanus and pertussis. Additional information about Biolik isavailable on its website, http://www.biolik.com.ua .
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company thatfocuses on the research, development, manufacture and commercialization ofvaccines that protect against human infectious diseases. Sinovac'scommercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combinedhepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac iscurrently developing Universal Pandemic Influenza vaccine and Japaneseencephalitis vaccine. Additional information about Sinovac is available onits website, http://www.sinovac.com . To be added to our distribution list,please email: [email protected].
Safe Harbor Statement
This announcement contains forward-looking statements. These statementsare made under the "safe harbor" provisions of the U.S. Private SecuritiesLitigation Reform Act of 1995. These forward-looking statements can beidentified by words or phrases such as "will," "expects," "anticipates,""future," "intends," "plans," "believes," "estimates" and similar statements.Among other things, the business outlook and quotations from management inthis press release contain forward-looking statements. Statements that arenot historical facts, including statements about Sinovac's beliefs andexpectations, are forward-looking statements. Forward-looking statementsinvolve inherent risks and uncertainties. A number of important factors couldcause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update anyforward-looking statement, except as required under applicable law.For more information, please contact: Helen G. Yang Sinovac Biotech Ltd. Tel: +86-10-8289-0088 x871 Fax: +86-10-6296-6910 Email: [email protected] Investors/Media: Stephanie Carrington / Janine McCargo The Ruth Group Tel: +1-646-536-7017/7033 Email: scarringto
